Canada· CA-DIN-02483645
CRYSVITA
A burosumab product containing burosumab, registered in Canada by KYOWA KIRIN, INC.. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Burosumab is registered in 14 of 19 countries.
Countries holding a registration under ATC M05BX05 (burosumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Burosumab · ATC M05BX05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- BUROSUMAB
- Manufacturer
- KYOWA KIRIN, INC.
- Country
- Canada (CA)
- ATC code
- M05BX05
- ATC class
- Burosumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
11 interactions on record for burosumab.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Burosumab · interactions on record
11 records
- 9 severe
- 2 moderate
Most severe, free to view
- DihydrotachysterolA11CC02severe
- CalcitriolA11CC04severe
- CalcifediolA11CC06severe
- ParicalcitolA11CC07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Burosumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCrysvita 10 mgKyowa Kirin Holdings
- CzechiaCRYSVITAKyowa Kirin Holdings B.V., Hoofddorp
- SpainCRYSVITA 10 MG SOLUCION INYECTABLEKyowa Kirin Holdings B.V.
- FinlandCrysvitaKyowa Kirin Holdings B.V.
- United KingdomCrysvita 10mg/0.33ml solution for injection pre-filled syringesKyowa Kirin Ltd
- Japanブロスマブ（遺伝子組換え）協和キリン
- SwedenCRYSVITA 10 mg Injektionsvätska, lösningKyowa Kirin Holdings B.V.
- United StatesCRYSVITAKyowa Kirin, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Crysvita
- Liechtenstein · Crysvita
- Norway · Crysvita
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1e59902-6584-4d0f-8928-2500f5731b2b GET /v1/drugs/f1e59902-6584-4d0f-8928-2500f5731b2b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02483645",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "M05BX05",
"schedule": [
"Prescription",
"Schedule D"
],
"drug_code": "97401",
"strengths": [
"30 MG"
],
"ahfs_class": null,
"substances": [
"BUROSUMAB"
],
"product_categorization": null
}See everything about burosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.